Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

436267

registered interest
date	08/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what representations he has received on reforming of NICE's procedure for appraisal of medicines.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	19235
answer	answer is ministerial correction date of answer 15/12/2015 answer text <p>We receive representations about the National Institute for Health and Care Excellence’s (NICE) technology appraisal programme from hon. Members, members of the public, clinicians and the pharmaceutical industry.</p><br /><p>NICE is the independent body that provides guidance on the prevention and treatment of ill health and the promotion of good health and social care and is responsible for its own processes and methodology.</p><br /><p>NICE regularly reviews these and its internationally renowned technology appraisal programme has evolved constantly to meet new challenges. NICE has demonstrated its ability to adapt to changes in the health and care environment, and we expect it will continue to evolve in the future, in particular through the recommendations of the Accelerated Access Review which NICE is centrally involved in.</p><br /><p>Further guidance on NICE’s processes of technology appraisal is available at:</p><br /><p>www.nice.org.uk/article/pmg19/chapter/Foreword</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/12/2015 16:28:02 answering member 4020 label Biography information for George Freeman
tabling member	4079 label Biography information for Julian Sturdy

800571

registered interest
date	04/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neuromuscular Disorders
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the (a) extent and (b) effect on patient care of variation in specialist services for multiple sclerosis and Parkinson's among clinical commissioning groups in England.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	117192
answer	answer is ministerial correction date of answer 12/12/2017 answer text <p>We know that variation exists between clinical commissioning groups (CCGs) in the provision of care for neurological conditions, such as Parkinson’s disease and multiple sclerosis. Whilst it is right that CCGs have autonomy to shape services for local populations, there is a range of work ongoing at a national level to identify unwarranted variation in order to drive improvement, including:</p><p> </p><p>- Through the RightCare programme, which was rolled out to every CCG in 2016/17, NHS England provides practical support to commissioners to tackle unwarranted variation and identify improvements and savings, including for neurological services;</p><p>- Public Health England’s Neurology intelligence network collates and interprets data on adult neurological conditions to provide intelligence for the National Health Service, policy makers, and clinicians; and</p><p>- The Getting it Right First Time programme, supported by NHS Improvement, expanded earlier in 2017 to include neurology and will soon provide insight to demonstrate the value of better neurological services both in hospitals and in the community.</p><p> </p><p>NHS England will continue to work with the Neurological Alliance (an umbrella organisation for neurological condition charities) to support the new national Neurology Advisory Group (NAG), led by consultant neurologist Professor Adrian Williams. The NAG brings together system partners, professional bodies stakeholders to align work to improve neurological care, and has working to understand how best to utilise new and emerging data in services and outcomes. More information on national initiatives to reduce unwarranted variation and drive improvement can be found at the following links:</p><p> </p><p><a href="http://www.england.nhs.uk/rightcare/" target="_blank">www.england.nhs.uk/rightcare/</a></p><p> </p><p><a href="http://www.gov.uk/guidance/neurology-data-and-analysis-a-guide-for-health-professionals" target="_blank">www.gov.uk/guidance/neurology-data-and-analysis-a-guide-for-health-professionals</a></p><p> </p><p><a href="http://gettingitrightfirsttime.co.uk/" target="_blank">gettingitrightfirsttime.co.uk/</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 117193 question first answered 12/12/2017 17:07:27 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

800572

registered interest
date	04/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neuromuscular Disorders
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the potential for improved specialist services for multiple sclerosis and Parkinson's delivering significant savings for the NHS; and if he will make a statement.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	117193
answer	answer is ministerial correction date of answer 12/12/2017 answer text <p>We know that variation exists between clinical commissioning groups (CCGs) in the provision of care for neurological conditions, such as Parkinson’s disease and multiple sclerosis. Whilst it is right that CCGs have autonomy to shape services for local populations, there is a range of work ongoing at a national level to identify unwarranted variation in order to drive improvement, including:</p><p> </p><p>- Through the RightCare programme, which was rolled out to every CCG in 2016/17, NHS England provides practical support to commissioners to tackle unwarranted variation and identify improvements and savings, including for neurological services;</p><p>- Public Health England’s Neurology intelligence network collates and interprets data on adult neurological conditions to provide intelligence for the National Health Service, policy makers, and clinicians; and</p><p>- The Getting it Right First Time programme, supported by NHS Improvement, expanded earlier in 2017 to include neurology and will soon provide insight to demonstrate the value of better neurological services both in hospitals and in the community.</p><p> </p><p>NHS England will continue to work with the Neurological Alliance (an umbrella organisation for neurological condition charities) to support the new national Neurology Advisory Group (NAG), led by consultant neurologist Professor Adrian Williams. The NAG brings together system partners, professional bodies stakeholders to align work to improve neurological care, and has working to understand how best to utilise new and emerging data in services and outcomes. More information on national initiatives to reduce unwarranted variation and drive improvement can be found at the following links:</p><p> </p><p><a href="http://www.england.nhs.uk/rightcare/" target="_blank">www.england.nhs.uk/rightcare/</a></p><p> </p><p><a href="http://www.gov.uk/guidance/neurology-data-and-analysis-a-guide-for-health-professionals" target="_blank">www.gov.uk/guidance/neurology-data-and-analysis-a-guide-for-health-professionals</a></p><p> </p><p><a href="http://gettingitrightfirsttime.co.uk/" target="_blank">gettingitrightfirsttime.co.uk/</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 117192 question first answered 12/12/2017 17:07:27 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

171625

registered interest
date	18/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Vulnerable Adults
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure that appropriate support systems are in place for older vulnerable people and people with dementia.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	219537
answer	answer is ministerial correction date of answer 09/01/2015 answer text <p>We are committed to ensuring that older vulnerable adults and their carers receive the best possible support in all settings through the Proactive Care Programme, and by ensuring all people aged 75 and over have a named general practitioner (GP) with overall responsibility for their care, providing continuity and oversight of their care. People living with dementia will benefit from this patient focused care.</p><p> </p><p> </p><p> </p><p>From April 2015, councils and the National Health Service will pool £5.3 billion of their local budgets under the Better Care Fund. This will require local authorities and the NHS to work together, and engage local partners, including voluntary sector organisations. It is expected that local areas will use some of this to improve care for people with dementia, such as providing access to dementia advisors, reminiscence services and counselling.</p><p> </p><p> </p><p> </p><p>Dementia is a key priority for this Government which is why in 2012 we launched the first ever Prime Minister’s Challenge on dementia to increase diagnosis rates, raise awareness and understanding and double funding for research in dementia by 2015.</p><p> </p><p> </p><p> </p><p>Since the launch of the Challenge, we have made significant progress across all three strands of the challenge including:</p><p> </p><p> </p><p> </p><p>- on 28 February 2014, the Secretary of State for Health announced his ambition for improving dementia care and support for people with dementia, their family and carers. This signalled the importance of a tailored plan of care as part of a package of high quality, personalised dementia care and support;</p><p> </p><p> </p><p> </p><p>- in the hospital setting, through the Dementia Commissioning for Quality and Innovation (CQUIN) reward (introduced from April 2012), with around 4,000 referrals a month, it is clear that more people with dementia in hospitals are being identified and assessed;</p><p> </p><p> </p><p> </p><p>- the Dementia Care and Support Compact, the care sector’s own response to the Prime Minister’s Challenge on Dementia, sets out a commitment to support the delivery of the challenge and improve care and support for people with dementia, their carers and families;</p><p> </p><p> </p><p> </p><p>- on 1 April, we put in place a new Dementia Directed Enhanced Service which has had over 80% take up by GPs to reward practices for facilitating timely diagnosis and support for people with dementia;</p><p> </p><p> </p><p> </p><p>- on 22 May, we launched the Dementia Roadmap web based navigation aid with the Royal College of General Practitioners to assist primary care staff effectively support patients, families and carers at the time of diagnosis and throughout the dementia journey; and</p><p> </p><p> </p><p> </p><p>- on 10 September 2014, NHS England published a new Dementia Toolkit aimed at helping GPs make a more timely diagnosis and what they can do in terms of vital post-diagnostic support.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 09/01/2015 13:48:20 answering member 1439 label Biography information for Norman Lamb
tabling member	4079 label Biography information for Julian Sturdy

778201

registered interest
date	26/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Multiple Sclerosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many and what proportion of unplanned or emergency hospital admissions for multiple sclerosis patients related to issues that could have been treated without going to hospital in (a) York and (b) England in the last 12 months for which records are available.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	109833
answer	answer is ministerial correction date of answer 02/11/2017 answer text <p>This information is not held centrally.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne grouped question UIN 109834 question first answered 02/11/2017 11:20:29 answering member 1542 label Biography information for Philip Dunne
tabling member	4079 label Biography information for Julian Sturdy

778202

registered interest
date	26/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Parkinson's Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many and what proportion of unplanned or emergency hospital admissions for Parkinson's disease related to issues that could have been treated without going to hospital in (a) York and (b) England in the last 12 months for which records are available.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	109834
answer	answer is ministerial correction date of answer 02/11/2017 answer text <p>This information is not held centrally.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne grouped question UIN 109833 question first answered 02/11/2017 11:20:29 answering member 1542 label Biography information for Philip Dunne
tabling member	4079 label Biography information for Julian Sturdy

781408

registered interest
date	31/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Chronic Fatigue Syndrome: Health Education
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps the Government is taking to raise awareness of myalgic encephalomyelitis among (a) healthcare professionals and (b) the general public.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	110590
answer	answer is ministerial correction date of answer 08/11/2017 answer text <p>There is information readily available on chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) for both healthcare professionals and the general public via NHS Choices website. Further information is also provided in the National Institute for Health and Care Excellence (NICE) clinical guidance which can be found via their website. This information is provided in formats suitable for both professionals and the public. Both the NHS Choices and NICE guidance can be found at the following links:</p><p><a href="http://www.nhs.uk/conditions/chronic-fatigue-syndrome-cfs/" target="_blank">www.nhs.uk/conditions/chronic-fatigue-syndrome-cfs/</a></p><p><a href="http://www.nice.org.uk/guidance/cg53" target="_blank">www.nice.org.uk/guidance/cg53</a></p><p>On 20 September 2017, NICE announced plans to undertake a full review of the guidance to ensure it reflects the latest available evidence.</p><p>Education and training is also an important feature in building the awareness of clinical professionals. In terms of education and training, the General Medical Council sets out the knowledge, skills and behaviours that new United Kingdom medical graduates must be able to demonstrate and Royal Medical Colleges, such as the Royal College of General Practitioners (RCGP) set the standards for postgraduate medical education in general practice. General practice is where most patients with CFS/ME are likely to be managed, and the condition is identified as a key area of clinical knowledge in the RCGP Applied Knowledge Test (AKT) content guide. The AKT is a summative assessment of the knowledge base that underpins general practice in the United Kingdom within the context of the National Health Service and is a key part of general practitioner’s qualifying exams.</p><p>Once fully qualified, clinicians are responsible for ensuring their own clinical knowledge remains up-to-date and for identifying learning needs as part of their continuing professional development. This activity should include taking account of new research and developments in guidance, such as that produced by NICE.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 08/11/2017 17:07:53 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

458532

registered interest
date	08/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Lipoedema
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will implement a treatment pathway for people who suffer from lipoedema to allow such people to receive liposuction on the NHS.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	30284
answer	answer is ministerial correction date of answer 15/03/2016 answer text <p>There are several different treatments available for the management of lipoedema such as compression therapy, exercise and massage. There is limited evidence on the efficacy of liposuction for the treatment of lipoedema, and it is not routinely available on the National Health Service.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 15/03/2016 11:19:17 answering member 3918 label Biography information for Jane Ellison
tabling member	4079 label Biography information for Julian Sturdy

781409

registered interest
date	31/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Chronic Fatigue Syndrome: Health Education
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans his Department has to mark International Awareness Day for Chronic Immunological and Neurological Diseases on 12 May 2018.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	110595
answer	answer is ministerial correction date of answer 08/11/2017 answer text <p>There are no specific plans at this point.</p><p> </p><p>NHS England’s Long Term Conditions Unit works with partners such as voluntary sector organisations (including those with a remit on chronic disease) to synchronise communications activity in line with many annual awareness days. The NHS England media team may also provide support through social media to maximise the reach of established campaigns.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 08/11/2017 17:11:15 answering member 4067 label Biography information for Steve Brine
tabling member	4079 label Biography information for Julian Sturdy

436266

registered interest
date	08/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he expects Orkambi to be appraised by NICE.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	19234
answer	answer is ministerial correction date of answer 15/12/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance on the use of Orkambi (lumacaftor in combination with ivacaftor) for the treatment of cystic fibrosis in people who are homozygous for the F508del mutation. NICE’s anticipated publication date for this guidance is July 2016. Further information is available at:</p><br /><p>www.nice.org.uk/guidance/indevelopment/gid-tag530</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/12/2015 16:20:22 answering member 4020 label Biography information for George Freeman
tabling member	4079 label Biography information for Julian Sturdy